Literature DB >> 17684845

Prevalence of hepatitis C virus infection and risk factors of drug using prisoners in Guilan province.

Z Mohtasham Amiri1, M Rezvani, R Jafari Shakib, A Jafari Shakib.   

Abstract

This was a cross-sectional prevalence study to determine the prevalence of hepatitis C virus (HCV) and high-risk behaviours in drug abusers admitted to prison in Guilan province, northern Islamic Republic of Iran. Subjects were asked about risk behaviours for acquiring HCV and blood was drawn for HCV antibody testing using ELISA techniques. Of 460 inmates, the mean duration of drug use was 8.9 years; 51.7% were opium users and 18.3% heroin users. HCV risk behaviours were common in this population and 209 inmates (45.4%) were HCV antibody positive (88.9% of intravenous drug abusers). HCV-positive status was significantly associated with intravenous drug use, having skin tattoos and number of times in prison.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17684845

Source DB:  PubMed          Journal:  East Mediterr Health J        ISSN: 1020-3397            Impact factor:   1.628


  23 in total

Review 1.  Epidemiology of hepatitis C virus in Iran.

Authors:  Reza Taherkhani; Fatemeh Farshadpour
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

Review 2.  Potential for human immunodeficiency virus parenteral transmission in the Middle East and North Africa: an analysis using hepatitis C virus as a proxy biomarker.

Authors:  Yousra A Mohamoud; F DeWolfe Miller; Laith J Abu-Raddad
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

3.  Prevalence, genotypes and factors associated with HCV infection among prisoners in Northeastern Brazil.

Authors:  Bruno Fernandes de Oliveira Santos; Nathalie Oliveira de Santana; Alex Vianey Callado Franca
Journal:  World J Gastroenterol       Date:  2011-07-07       Impact factor: 5.742

Review 4.  Hepatitis C virus infection in the Middle East and North Africa "MENA" region: injecting drug users (IDUs) is an under-investigated population.

Authors:  S Ramia; N M Melhem; K Kreidieh
Journal:  Infection       Date:  2012-01-12       Impact factor: 3.553

5.  Global prevalence of hepatitis C in prisoners: a comprehensive systematic review and meta-analysis.

Authors:  Nader Salari; Niloofar Darvishi; Mahvan Hemmati; Shamarina Shohaimi; Yasaman Ghyasi; Farahnaz Hossaini; Mohammad-Rafi Bazrafshan; Hakimeh Akbari; Masoud Mohammadi
Journal:  Arch Virol       Date:  2022-02-14       Impact factor: 2.574

Review 6.  Molecular and contextual markers of hepatitis C virus and drug abuse.

Authors:  Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

7.  HCV, HBV, and HIV seroprevalence, coinfections, and related behaviors among male injection drug users in Arak, Iran.

Authors:  Amitis Ramezani; Reihaneh Amirmoezi; Jonathan E Volk; Arezoo Aghakhani; Nader Zarinfar; Willi McFarland; Mohammad Banifazl; Ehsan Mostafavi; Ali Eslamifar; Masoomeh Sofian
Journal:  AIDS Care       Date:  2014-02-06

8.  Hepatitis C Virus and Associated Risk Factors among Prison Inmates with History of Drug Injection in Isfahan, Iran.

Authors:  Nazila Kassaian; Peyman Adibi; Alireza Kafashaian; Majid Yaran; Zary Nokhodian; Parisa Shoaei; Razieh Hassannejad; Anahita Babak; Behrooz Ataei
Journal:  Int J Prev Med       Date:  2012-03

9.  Intravenous drug use and hepatitis C virus in iran.

Authors:  Mehdi Zobeiri; Peyman Adibi; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2012-01-20       Impact factor: 0.660

10.  Annual Registry for Hepatitis C and Hepatitis B is Needed for Predicting the Burden of Hepatocellolar Carcinoma in Iran.

Authors:  Zeinab Fazeli; Mohsen Vahedi; Sara Ashtari; Mohamad Amin Pourhoseingholi
Journal:  Hepat Mon       Date:  2013-02-24       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.